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Available online 13 March 2015Polygenic risk scores, based on risk variants identiﬁed in genome-wide-association-studies (GWAS), explain a
considerable portion of the heritability for schizophrenia (SZ) and bipolar disorder (BD). However, little is
known about the combined effects of these variants, although polygenic neuroimaging has developed into a
powerful tool of translational neuroscience. In this study, we used genome wide signiﬁcant SZ risk variants to
test the predictive capacity of the polygenic model and explored potential associations with white matter
volume, a key candidate in imaging phenotype for psychotic disorders.
By calculating the combined additive schizophrenia risk of seven SNPs (signiﬁcant hits from a recent schizophre-
nia GWAS study), we show that increased additive genetic risk for SZ was associated with reduced white matter
volume in a group of participants (n=94) consisting of healthy individuals, SZ ﬁrst-degree relatives, SZ patients
and BD patients. This effect was also seen in a second independent sample of healthy individuals (n= 89). We
suggest that a moderate portion of variance (~4%) of white matter volume can be explained by the seven hits
from the recent schizophrenia GWAS.
These results provide evidence for associations between cumulative genetic risk for schizophrenia and interme-
diate neuroimaging phenotypes in models of psychosis. Our work contributes to a growing body of literature
suggesting that polygenic risk may help to explain white matter alterations associated with familial risk for
psychosis.
Crown Copyright © 2015 Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Neurobiological models of schizophrenia (SZ) and bipolar disorder
(BD) implicate altered interregional connectivity and suggest that
some of the changes in white matter structure may be heritable
(Kaymaz and van Os, 2009; McDonald et al., 2004; McIntosh et al.,
2006). This hypothesis is supported by studies that show that decreased
white matter volume may be an indicator of genetic liability to both
schizophrenia (Francis et al., 2013; Kaymaz and van Os, 2009;sychosomatic Medicine and
oimaging, Heinrich-Hoffmann-
.: +49 69 6301 7181; fax: +49
el).
r Inc. This is an open access article uMcDonald et al., 2004; McIntosh et al., 2006; Oertel-Knochel et al.,
2012; van Haren et al., 2012) and bipolar disorder (Emsell and
McDonald, 2009; Hasler et al., 2006; Matsuo et al., 2012). Genome
wide association studies (GWAS) are identifying an increasing number
of single-nucleotide polymorphism (SNPs), signiﬁcantly associated
with risk for schizophrenia and/or bipolar disorder (Cardno and
Owen, 2014; GWAS Consortium, 2011; Psychiatric GWAS Consortium
Bipolar Disorder Working Group, 2011; Schulze et al., 2014; Smoller
et al., 2013), although the functional mechanisms by which these vari-
ants confer risk for psychosis remain largely unknown. A recent study
reported that a combined measure of schizophrenia risk variant load
(polygenic schizophrenia score or risk proﬁle score; RPS) was signiﬁ-
cantly associated with white and total brain volume, in both healthy
and affected individuals (Terwisscha van Scheltinga et al., 2013). The
study further suggested that the association was driven by a smaller
number of SZ-associated SNPs (n=186) than the SNP set that best pre-
dicted WM volume (n = 2020) or diagnosis (n = 14,751). However,nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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risk score and white matter volume, using the same discovery data set
(PGC-SZ1; GWAS Consortium, 2011) and largely the same SNPs (n =
185) hypothesised to be associated with both schizophrenia and WM
volume. Papiol et al. (2014) suggested there were only minor differ-
ences between study designs, which were unlikely to account for
between-study variability (including sample size, ethnicity, genotyping
methods and scanner type). Considering that disrupted white matter
has been repeatedly observed in relatives of patientswith schizophrenia
and patients with bipolar disorder (Emsell andMcDonald, 2009; Francis
et al., 2013; Hasler et al., 2006; Matsuo et al., 2012; McDonald et al.,
2004; McIntosh et al., 2006; Oertel-Knochel et al., 2012; van Haren
et al., 2012), we suggest that common genetic risk factors should
contribute to the neurobiological mechanisms that underlie volumetric
white matter disturbances. At present, it is not known whichmolecular
pathways are responsible for modulating white matter at the genetic
level, and thus in the present study, we employ an RPSmodel calculated
only using robust, genome-wide signiﬁcant SNPs for schizophrenia
(GWAS Consortium, 2011). We aim to explore the association between
additive effects of these seven schizophrenia risk SNPs (7-SNP SZ-RPS)
with white matter volume. We additionally base our hypothesis
on the ﬁndings of Terwisscha van Scheltinga et al. (2013) who reported
that at least one of these top-hits from the PGC-SZ1 study (rs17662626
near PCGEM1)was implicated in this prior association, and risk associat-
edwith these highly signiﬁcant SNPsmay producemore reliable associ-
ations with imaging phenotypes than SNPs added to a polygenic model
with less stringent p thresholds and less robust ORs. We hypothesise
that larger risk proﬁle scores are associated with reduced white matter
volume across the psychosis spectrum.
2. Materials and methods
2.1. Participants
2.1.1. Frankfurt site
A total of n = 94 participants were included and divided into four
groups: SZ patients, ﬁrst-degree relatives, BD patients and healthy
controls. The SZ patient group consisted of n = 24 patients of the De-
partment of Psychiatry, Psychosomatic Medicine and Psychotherapy of
the University of Frankfurt, Germany (mean age [years]: M = 38.10
[SD = 10.34]) diagnosed according to the DSM-IV criteria (Guze,
1995). At the time of measurement, all patients were treated withTable 1
Frankfurt sample: Demographic, clinical and cognitive data for all subject groups. SZ= schizoph
phrenia and CON = controls. RHS = Revised Hallucination Scale and MWT=multiple word c
relatives of patients with schizophrenia, n = 24 patients with schizophrenia, n = 20 patien
VBM sample (n= 94). p= signiﬁcant on an α ≤ 0.05-threshold.
SZ Mean ± SD REL Mean ± SD BD Me
N 24 12 20
Gender (f/m) 10/14 7/5 11/9
Years of education 14.13 ± 3.10 16.00 ± 2.12 15.54
Parental education
Mother 13.15 ± 2.65 14.11 ± 3.10 13.08
Father 14.08 ± 2.54 13.12 ± 3.22 14.12
Age 38.10 (10.34) 45.12 (12.67) 39.00
MWT-B 105.55 (9.90) 107.45 (101.43) 108.13
Years of illness 13.65 ± 6.81 10.11
Age of onset 21.10 ± 4.51 29.17
Medication
(4 weeks stable at minimum)
27 atypical neuroleptics 30 mo
anti-d
BDI II 10.81
BRMAS 0.77 (1
PANSS sum 66.41 (16.43)
PANSS positive 17.41 (5.34)
PANSS negative 17.56 (5.90)
PANSS general 33.68 (8.49)atypical antipsychotics. We assessed present psychopathological symp-
toms in the SZ group using the Positive and Negative Symptom Scale
(PANSS) (Kay et al., 1987). The relative group consisted of n = 12
ﬁrst-degree unaffected relatives of SZ patients (M [years] = 45.12
[12.67])whowere requested to provide a letter from the attending psy-
chiatrist conﬁrming the index patients3 diagnosis.We further conducted
a semi-structured interview with the relatives (German version of the
Premorbid Adjustment Scale (PAS)) (Krauss et al., 2000) in order to fur-
ther back-up the index patients3 diagnosis. A third group included n=
20 patients with bipolar disorder I (M [years] = 39.00 [12.10]) as de-
ﬁned by the DSM-IV criteria (APA, 1994) and diagnosed by a board-
certiﬁed psychiatrist at the Dept. of Psychiatry and Psychotherapy of
Frankfurt University Medical School. Current depressive symptoms
were assessed using the German version of the Beck Depression Inven-
tory II (BDI II; Hautzinger et al., 2006), and current mania symptoms
were assessed using the German version of the Bech Rafaelsen Mania
Scale (BRMAS; Bech, 1981). At the time of the measurements, all pa-
tients were in disease remission (see deﬁnition in the clinical testing),
were without any comorbid axis I or II disorders (including substance
abuse or addiction) and were on stable medication at a minimum of
4weeks prior tomeasurement (see Table 1). Remitted state in the bipo-
lar patient group was deﬁned by BDI II scores of b 18 (M BD patients =
10.81 [9.56]) and BRMAS scores of b 7 (M BD patients = 0.77 [1.79])
(see Table 1 for further sociodemographic details and Supplementary
Table S1 for medication status).2.1.1.1. Comparison of the two patient groups3 sociodemographics. There
were some differences in the sociodemographic variables between the
patient groups, although theywerematched for age, gender and educa-
tion. Schizophrenia and bipolar patients differed regarding age of onset
(SZ:M [years] = 21.10 [4.51]; BD:M [years] = 29.17 (11.68]; t= 8.37,
p= 0.03) and duration of illness (SZ:M [years] = 13.65 [6.81]; BD: M
[years] = 10.11 [7.08]; t= 6.54, p= 0.04). This was due to the clinical
characteristics of the diseases, as the mean age of onset for both disor-
ders is different (about 21–26 years for schizophrenia, about 30 years
for bipolar disorder), and duration of illness depends on the age of
onset and the mean age of the samples, and thus will generally differ
in age-matched groups with different psychotic disorders.
During the time of the study patients had to be in (at least partial)
remission in order for them to comply with the scanning requirements.
All patientswere onmaintenancemedication, and themedication dosesrenia patients, BD= bipolar patients, REL= ﬁrst-degree relatives of patients with schizo-
hoice test. VBM data were available for 94 participants (n= 38 healthy controls, n= 12
ts with bipolar disorder). The table contains sociodemographic and clinical data for the
an ± SD CON Mean ± SD Signiﬁcance
38 94
20/18 Kruskal–Wallis, p = 0.422
± 2.08 16.43 ± 1.76
CON vs. SZ: t = 2.22, p = 0.006
F = 4.76, p = 0.006
± 3.12 13.50 ± 3.19 F = 0.30, ns
± 3.45 14.80 ± 2.51 F = 1.43, ns
(12.10) 37.15 (11.14) F = 2.13, p = 0.114
(7.65) 112.01 (7.77) F = 2.42,p = 0.080
± 7.08
± 11.68
od stabiliser + 12
epressants
(9.56) 1.98 (3.58) t = 37.79, p b 0.001
.79) 0.56 (1.01) z = −0.36, ns
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computed the chlorpromazine equivalents for each SZ patient using the
formula by Woods (2003), and ‘amitryptilin equivalents’ for each BD
patient as described by Ali (1998), and assessed potential inﬂuence of
the equivalents on the main imaging results.
The control group comprised n= 38 healthy controls (M [years] =
37.15 [11.14]) (see Table 1)whowere recruited through localmedia ad-
vertisements. The exclusion criteria for the control subjects and for the
relatives were any axis I and axis II disorders according to DSM-IV,
left-handedness, current drug-abuse, and neurological diseases.
All subjects underwent the Structured Clinical Interview for DSM-IV
(SCID; Wittchen et al., 1996) in order to conﬁrm the clinical diagnosis
(in the patient groups), or to ensure that none of the non-patient partic-
ipants suffered from any psychiatric disorder (relatives, controls). None
of the controls had any positive family history of psychosis. All groups
werematched for handedness (all right handed;measuredwith The Ed-
inburgh Handedness Inventory (Oldﬁeld, 1971)) age, gender, education
and parental education. SZ patients and controls showed signiﬁcant dif-
ferences in the years of education but the years of education in the
parents3 group was comparable, and the signiﬁcant differences are due
to illness speciﬁcations.
We also assessed verbal intelligence using theMultiple ChoiceWord
Comprehension Test (MWT-B; Lehrl, 2005) in order to rule out that po-
tential group differences in these scores may inﬂuence themain results.
The participants showed no signiﬁcant group effect in the scores of the
MWT-B (verbal intelligence) (F = 2.42, ns) (see Table 1). The partici-
pants were provided with a description of the study and gave written
informed consent before participation. Experimental procedures were
approved by the ethical board of the medical department of the
Goethe-University, Frankfurt, Germany.
2.1.2. Cardiff site
We recruited an opportunistic sample comprising of n = 89 right-
handed Caucasian healthy controls (M [years] = 24.42 [SD = 4.58]).
We administered a detailed biographical and sociodemographic ques-
tionnaire, and included comparable measures to those used in the
Frankfurt sample, in order to ensure that none of the controls had a
lifetime history of mental or behavioural disorders (including any axis
I or axis II disorder), use of psychotropic medication or neurological dis-
ease. After explaining the study we obtained written informed consent.
The study was approved by the research ethics committee of the School
of Psychology, Cardiff University.
2.2. MRI data acquisition
2.2.1. Frankfurt site
MRI data were acquired using a Trio 3 T scanner (Siemens, Erlangen,
Germany) at Frankfurt University with a standard transmit–receive
head coil. Anatomical data consisted of one MDEFT (Modiﬁed Driven
Equilibrium Fourier Transform) sequence (Deichmann et al., 2004)
with 1 × 1 × 1 mm3 voxel size and 176 slices.
2.2.2. Cardiff site
MRI data were acquired using a 3 T GT HDx system at the Cardiff
University Brain Research Imaging Centre (CUBRIC), School of Psychol-
ogy, Cardiff University. High resolution T1-weighted three dimensional
images were acquired using a fast spoiled gradient echo sequence
(FSPGR) with 172 contiguous sagittal slices of 1 mm thickness.
All anatomical MRI scans were reviewed by a neuroradiologist who
did not ﬁnd any pathology, i.e., focal or local atrophy, lacunar infarcts
or extensive microangiopathy.
2.3. MRI image processing
2.3.1. Frankfurt & Cardiff sites
For all subjects, we used standard Voxel-basedmorphometry (VBM)
routines including the DARTEL tool to preprocess the anatomical datasets, resulting in non-linear, modulated, smoothed images, deﬁned as
‘absolute volume’. This process was performed with SPM8 (statistical
parametric mapping [Wellcome Department of Imaging Neuroscience,
London, UK]) running on a current version of the MATLAB software.
First, all white matter images went under rigorous quality control
checked by a) visual inspection (for artefacts, structural abnormalities
and pathologies) and statistically (for homogeneity of covariance and
distribution). Second, customised T1 templates and prior images of
grey matter (GM), white matter (WM) and cerebro-spinal ﬂuid (CSF)
were created from all participants. For the segmentation, we followed
the steps provided by the SPM8 guidelines (light bias regularisation
[0.001], 60 mm bias FWHM cut-off, warping regularisation of 4, afﬁne
regularisation to the ICBM European brain template (linear registra-
tion), sampling distance of 3, manual quality check; for details of the
preprocessing steps, see Oertel-Knochel et al., 2012). Finally, the images
were smoothed (Ashburner and Friston, 2000) with a Gaussian kernel
of 8 × 8 × 8 mm3 (FWHM), whereby the intensity of each voxel was
replaced by the weighted average of the surrounding voxels, in essence
blurring the segmented image. Considering the results previously re-
ported (Terwisscha van Scheltinga et al., 2013), we only sampled
white matter volume, using white matter masks provided by the WFU
PickAtlas (http://www.fmri.wfubmc.edu/downloads) toolbox in SPM8
(Maldjian et al., 2003). Absolute white matter volume estimates
(measured in cubic decimetres (dm3)) for each white matter
mask were extracted using the MarsBaR toolbox (http://marsbar.
sourceforge.net/).2.4. Genotyping, SNP selection and risk proﬁle score calculation
2.4.1. Frankfurt site
Genotyping of the seven candidate SNPs was performed using the
Illumina GoldenGate assay (Illumina, Inc., San Diego, CA, USA) using
the BeadXpress platform. Assays were designed for the experiment
using Illumina3s Assay Design Tool (http://support.illumina.com/array/
array_software/assay_design_tool.ilmn). In total, 94 blood-derived
genomic DNA samples were genotyped to verify the seven SNPs (for
SNP sequences see Supplementary Table S2). Nucleic acid quality and
concentrationwere evaluated using PicoGreen assay (Life Technologies,
Carlsbad, CA, USA). GoldenGate genotypingwas performed according to
the manufacturer3s protocols. Genotype calling and annotation were
performed using GenomeStudio (Illumina, Inc., San Diego, CA, USA).2.4.2. Cardiff site
Genomic DNA was obtained from saliva using Oragene OG-500
saliva kits. Individuals were genotyped using customised Illumina
HumanCoreExome BeadChip SNP genotyping arrays (Illumina,
Inc., San Diego, CA). Quality control was implemented in PLINK
(Purcell et al., 2007). Individuals were excluded for ambiguous sex,
genotyping completeness less than 97%, cryptic relatedness (up to
third degree relatives by identity of descent), and non-European ethnic-
ity as detected in iterative EIGENSTRAT analyses of an LD-pruned data
set.2.4.3. Discovery sample
Our risk proﬁle score (7-SNP SZ-RPS) calculation was performed
using the method described by Purcell et al. (International
Schizophrenia Consortium et al., 2009). Brieﬂy, schizophrenia risk
(based on odds ratios; ORs) was estimated from an international
GWAS of 9394 schizophrenia cases and 12,462 controls (PGC-
schizophrenia stage-one; GWAS Consortium, 2011). Risk proﬁle scores
for schizophrenia were calculated by averaging the number of risk al-
leles for each SNP for each person, weighted by the natural logarithm
of its OR, estimated by the schizophrenia GWAS (GWAS Consortium,
2011).
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We considered SNPs that were signiﬁcantly associated with schizo-
phrenia risk based on the recent genome scan for schizophrenia
(GWAS Consortium, 2011). SNP genotype data were available for
seven SNPs that were associated with schizophrenia at a genome-
wide level (MIR137 [rs1625579] p = 1.59 × 10−11; CCDC68
[rs12966547] p = 2.60×10−10; CNNM2 [rs7914558] p =
1.82×109; NT5C2 [rs11191580 1] p = 11×10−8; MMP16
[rs7004633] p = 2.75×10−8; CSMD1 [rs10503253] p = 4.14×10−8;
PCGEM1 [rs17662626] p = 4.65×10−8). A single risk proﬁle score
(7-SNP SZ-RPS) based upon the additive schizophrenia risk of these
seven SNPs was created for each individual in the Frankfurt (n =
94) and Cardiff (n = 89) samples.2.5. Statistical analysis
All statistics were performed in IBM SPSS Statistics v21. Initial group
differences were explored with a univariate general linear model with
group/diagnoses and gender as between subject factors and age/ICV re-
siduals (ICV residuals were created by regressing out WM volume:
ICVRES) as covariates. In order to explore the putative effects of our 7-
SNP SZ-RPS onWM volume above and beyond the potential confound-
ing effects of age, group ICVRES and diagnoses/group,we performed in a
two-step hierarchal regression analyses. Hierarchal regression analyses
were performed on white matter volume for each sample (Frankfurt
site, Cardiff site) separately. In the ﬁrst step of the model, covariates of
interest were added (Frankfurt: age, gender, ICV & group/diagnoses;
Cardiff: age, gender, ICV). We followed up any group differences and/
or associations in the ﬁrst step of the hierarchal regression with one-
way ANOVAs/independent sample t-test and bivariate correlations,
respectively. In the second step of the model, we used 7-SNP SZ-
RPS for SZ as a potential predictor of WM above and beyond the po-
tential effects of demographic confounds. We then proceeded to run
two independent partial bivariate correlations between WM volume
and 7-SNP SZ-RPS, controlling for potential confounds such as age,
gender, intracranial volume (ICV residuals; regressing out WM)
and group/diagnosis.3. Results
3.1. Imaging effects
3.1.1. Frankfurt Site
Hierarchical regression revealed that group/diagnosis signiﬁcantly
predicted white matter volume (β=−0.349, p = 0.001). Univariate
analysis (adjusted for age, gender and ICVRES) conﬁrmed a signiﬁcant
effect of group/diagnosis (F3,84 = 5.998, p = 0.0009), with corrected
pairwise comparisons revealing that the group effect was driven by
larger WM volume in healthy controls compared to: schizophrenia pa-
tients (pCORRECTED = 0.004), relatives (pCORRECTED = 0.034) and bipolar
patients (pCORRECTED = 0.037). Post-hoc independent samples t-test
analysis conﬁrmed that the group differences in WM volume between
healthy controls and ﬁrst-degree relatives (t(48) = 3.452, p = 0.001),
between the controls and schizophrenia patients (t(60) = 3.944,
p ≤ 0.001) and between controls and bipolar patients (t(56) = 2.572,
p= 0.008) with higher values for healthy controls in all the cases (see
Fig. 1a). There were no signiﬁcant differences between relatives of
schizophrenia patients, schizophrenia patients and bipolar patients
(in all cases; p N 0.50). Critically, the polygenic model predicted WM
volume above and beyond potentially confounding effects of age, gen-
der, ICV and group/diagnosis (ΔR2 = 0.044, β=−0.211, p = 0.033).
Post-hoc partial correlations (controlling for age, gender and
ICVRES) revealed that this association was signiﬁcant in the healthy
control group (r= –0.364, p=0.031) and at the trend level in the bipo-
lar disorder group (r = –0.452, p = 0.068), but not signiﬁcant in therelatives (r= 0.288, p= 0.497) or schizophrenia patients (r= –0.121,
p= 0.600).
3.1.2. Cardiff Site
The hierarchical regression revealed that 7-SNP SZ-RPS predicted
WM volume (ΔR2 = 0.051, β=−0.227, p= 0.037). Bivariate correla-
tions conﬁrmed a negative association between WM volume and 7-
SNP SZ-RPS, controlling for age and group/diagnosis using the PGZ-SZ-
one (Frankfurt: r = –0.266, p = 0.033; Cardiff: r = –0.226, p =
0.037) (See Fig. 1b-c). A regression performed on the combined sample
(Stonnington et al., 2008) (independent sample, z-transformed WM
volume) conﬁrmed the signiﬁcant negative association between WM
volume and 7-SNP SZ-RPS using the PGC-SZ-one ORs (ΔR2 = 0.042,
β=−0.207, p= 0.005). We then performed a post-hoc regression to
explore the individual effects of each of the seven SNPs onwhitematter
volume across the whole sample. The seven SNPs (individual effects;
rather than polygenic model) also predicted WM volume (controlling
for age, gender, ICV and group/diagnoses) (FΔ = 2.976 p = 0.006).
We observed that four of the seven SNPs were nominally associated
with white matter volume (above and beyond the effects of age and
group/diagnoses) including rs10503253 in CSMD1 (β=−0.242, p =
0.001), rs12966547 in CCDC68 (β= −0.168, p = 0.026), rs1625579
in MIR137 (β = −0.161, p = 0.034) and rs17662626 near PCGEM1
(β=−0.141, p= 0.05).
3.2. Demographics & 7-SNP SZ-RPS (both sites)
The 7-SNP SZ-RPS did not differ between the diagnostic groups
(F3,93 = 1.617, p = 0.191) within the Frankfurt sample. There was no
correlation between 7-SNP SZ-RPS and age in either the Frankfurt
(r=0.036, p=0.731) or the Cardiff (r=0.004, p=0.986) sample, sug-
gesting that the potential associations between 7-SNP SZ-RPS and WM
were not a) confounded by age-related reductions in WM and b) not
due to shared variance of 7-SNP SZ-RPS and age on WM. In the ﬁrst
step of the model for each sample, age was not a signiﬁcant predictor
of WM volume (Frankfurt: β = −0.144, p = 0.146; Cardiff: β =
0.027, p= 0.799).
3.3. Potential inﬂuence of sociodemographics or medication onmain imag-
ing results
There were no differences in 7-SNP SZ-RPS between genders at the
Cardiff site (F1,88 = 0.196, p = 0.659), in the Frankfurt site (F1,92 =
0.470, p = 0.495) or in the combined sample (F1,182 = 0.604, p =
0.438). We also did additional bivariate correlation analyses (2-tailed)
in order to control for potential inﬂuence of age of onset and duration
of illness on themain imaging results. Here, results indicate that neither
age of onset nor duration of illness had any signiﬁcant association with
the VBM parameters in any of the patient groups (p N 0.05). We com-
puted the chlorpromazine equivalents for each SZ patient using the for-
mula by Woods (2003), and ‘amitryptilin equivalents’ (Ali, 1998) for
each BD patient. These scores were used to compute correlation analy-
ses between the main imaging results and the intensity of medication.
We did not ﬁnd any inﬂuence of these scores on the main results
(p N 0.05).
4. Discussion
A growing number of studies are adopting a polygenic approach
when exploring neuropsychiatric clinical phenotypes (Dudbridge,
2013). Recent research suggests that up to 32% of the variance in risk
for schizophrenia may be captured by the cumulative effects of SNPs
(Lee et al., 2012; Ripke et al., 2013). Furthermore, several studies have
found associations between increased psychiatric polygenic risk (RPS)
and both brain structure (Holmes et al., 2012; Papiol et al., 2014;
Whalley et al., 2013) and brain function (Walton et al., 2013b; Walton
Fig. 1. Frankfurt sample: a.Whitematter volumes (dm3) across groups, b. correlation betweenwhitematter volumes (dm3) and 7-SNP-RPS scores individually for each group in the Frank-
furt sample, c. correlation betweenwhitematter volumes (dm3) and 7-SNP-RPS scores across the Cardiff sample. Post-hoc analysis revealed that compared to healthy controls, whitemat-
ter volumewas reduced in relatives of schizophrenia patients (p=0.004), schizophrenia patient relatives (p=0.034) and bipolar patients (p=0.037). p-Values are adjusted formultiple
comparisons (Bonferroni corrected). Bivariate correlations conﬁrm a negative association betweenWMvolume and 7-SNP SZ-RPS, controlling for age, gender, ICVRES (anddiagnosis in the
Frankfurt sample) (Frankfurt: r=−0.266, p= 0.033; Cardiff: r=−0.226, p= 0.037). SZ= schizophrenia patients, BD= bipolar patients, REL = ﬁrst-degree relatives of patients with
schizophrenia, and CON= controls. VBM data were available for 94 participants (n= 38 healthy controls, n= 12 relatives of patients with schizophrenia, n= 24 patients with schizo-
phrenia, n= 20 patients with bipolar disorder). p= signiﬁcant on an α b 0.05-threshold. ** denotes p b 0.01, * denotes p b 0.05. NB: there were no statistical outliers in WM volume in
either sample. Shaded grey bars represent 95% conﬁdence intervals.
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both the clinical phenotype of schizophrenia and familial genetic risk
were associated with reduced white matter volume, as indicated by
the differences in white matter volume between the healthy controls
and SZ ﬁrst-degree relatives, and between healthy controls and schizo-
phrenia patients. This result supports numerous ﬁndings implicating
white matter differences in the familial genetic risk associated with
schizophrenia (Francis et al., 2013; Oertel-Knochel et al., 2012; van
Haren et al., 2012). Moreover, we additionally included a group of BD
patients, as they also show reduction in WM volumes, are part of the
psychosis spectrum and add more power to the study. Therefore, theinitial genetic difference between HC N REL = SZ is our ‘working inter-
mediate phenotype’. We show that this is a ‘genetic’ difference before
observing associations with our 7-SNP SZ-RPS.
Crucially, the present study also demonstrated that reduced whole
brain white matter was associated with 7-SNP SZ-RPS as measured by
the cumulative effect of seven SZ risk loci, which was selectively signif-
icant in both healthy control groups. In contrast to previous polygenic
imaging studies, this is theﬁrst study to use a targeted set of schizophre-
nia -associated genome wide signiﬁcant SNPs rather than arbitrary p-
threshold cut-offs. It is noteworthy that the estimates for the variance
in brain structure explained by the polygenic effects of in our study
769V. Oertel-Knöchel et al. / NeuroImage: Clinical 7 (2015) 764–770(R2 = .042) are comparable to the R2 estimates (R2 = .054) originally
found by Terwisscha van Scheltinga et al. (2013), which is striking con-
sidering that our estimate is only based on a set of seven SNPs.5. Limitations
Although the study was moderately well-powered for an imaging
sample, the 7-SNP SZ-RPS did not delineate our participants based on
diagnosis. This suggests that our 7-SNP SZ-RPS model may be under-
powered to detect clinical phenotypes. However, as the 7-SNP-RPS
was associated with WM volume across our sample sites, we feel that
it may reﬂect a small but signiﬁcant component of psychosis-related
pathophysiology. We did not see an effect of 7-SNP SZ-RPS in the rela-
tive or SZ group, but these subsamples may be underpowered or affect-
ed by shared environmental confounds. Although we are unable to
directly compare our results with those of Terwisscha van Scheltinga
et al. (2013) and Papiol et al. (2014) because we did not have
genome-wide data for a proportion of our participants, our additional
evidence suggests ﬁrstly that the genetic susceptibility for schizophre-
nia is associated with variance in white matter volume and secondly,
that this effect may be mediated through a small set of relatively robust
risk variants.
We were however, able to replicate previous ﬁndings suggesting an
involvement of rs17662626 (near PCGEM1) in the volumeofwhitemat-
ter (Terwisscha van Scheltinga et al., 2013). Other studies looking at in-
dividual risk alleles used in themodel (such asMIR137, CSMD1, CNNM2)
and other psychosis risk SNPs have shown no association with white
matter volume (Cousijn et al., 2014; Rose et al., 2013; Rose et al.,
2014; Tesli et al., 2013). We suggest that the effect sizes of common
risk alleles for SZ are small, so additive models like our 7-SNP SZ-RPS
may help to elucidate the combined effects of multiple loci on SZ inter-
mediate phenotypes. Our results support the hypothesis that a subset of
schizophrenia risk variants are related to the maturation of white mat-
ter volume, suggesting that common variation in these risk loci may in-
crease schizophrenia susceptibility through perturbation of brain
connectivity (Voineskos, 2015). Future work should explore biological-
ly informed polygenic models in order to disentangle the molecular
pathways that confer susceptibility for deﬁcits in white matter
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